Article

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction

Department of Pathology and Division of Hematology-Oncology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9073, USA.
Transfusion (Impact Factor: 3.57). 10/2009; 50(2):487-92. DOI: 10.1111/j.1537-2995.2009.02413.x
Source: PubMed

ABSTRACT Plasma and platelets (PLTs) are often transfused to correct mild to moderately abnormal laboratory values. Our objective was to reduce unnecessary plasma and PLT transfusions to nonbleeding patients by prospective triage and education of end users in evidence-based hemostasis and transfusion medicine practices.
Using the Parkland Memorial Hospital's transfusion service and admission database as the data source, this study comprises the comparison of transfusion data on plasma and PLT use between pre- (2000-2002) and posttriage (2003-2006) periods. Yearly transfusion and wastage data on red blood cells (RBCs), plasma, and PLTs and yearly hospital admissions, trauma visits, and surgical procedures were extracted retrospectively for the study.
The study revealed that implementation of triage resulted in a significant reduction of plasma (60%) and PLT (25%) transfusions, saving more than $3,000,000 over 4 years.
Prospective triage and evidence-based transfusion practice education reduced unnecessary plasma and PLT transfusions and health care costs.

0 Followers
 · 
74 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The majority of fresh-frozen plasma (FFP) is transfused in the United States in the management of acquired bleeding disorders. The prothrombin time (PT), and its derivative the international normalized ratio (INR), is the most common test used to detect the presence and gauge the severity of these disorders. Observation studies have shown that the PT correlates poorly with clinical bleeding and that transfusion of plasma often achieves no measurable change in the INR nor is of any known clinical benefit. Data on FFP and red blood cell transfusions and measures of hospital activity and mortality were collected over a 12-year period. The first 3 years were baseline years, the next 3 years were physician education years, and in the last 6 years all requests for FFP were screened. Orders were discouraged if the INR was less than 2.0 in the absence of active bleeding and the use of vitamin K was encouraged if the patient was taking warfarin. This program ultimately resulted in an approximate 80% reduction in transfused FFP using the average of the baseline years compared to the average of the last 3 years (157 ± 19 units FFP/1000 discharges vs. 30 ± 15, p < 0.01, respectively). Overall, hospital activity remained largely unchanged or increased. No unexpected bleeding was reported, which was attributed to a failure to transfuse FFP, and inpatient mortality rate decreased during these 12 years. A program of engagement and interdiction using evidence-based guidelines can successfully decrease the use of FFP without any observable increase in unexpected bleeding.
    Transfusion 10/2010; 51(4):754-61. DOI:10.1111/j.1537-2995.2010.02900.x · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Three basic categories of hemostats are widely used in surgery today: chemical agents, thermal devices, and mechanical methods that use pressure or ligature to slow bleeding. Each has its benefits and limitations. However, nanotechnology is rapidly ushering in new medical technologies. This review focuses on the 'nanohemostat', a new class of hemostatic agent that stops bleeding in less than 15 seconds by using (RADA)4, referred to as nanohemostat-1 (NHS-1), a synthetic biological material that self-assembles at the nanoscale when applied to a wound, and compares it to the characteristics of the 'ideal hemostat'.
    Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 01/2011; 3(1):70-8. DOI:10.1002/wnan.110 · 4.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: We previously reported that in the year 2006, approximately 35% of the transfusions administered in the Intermountain Healthcare neonatal intensive care units (NICU) were noncompliant with our transfusion guidelines. In January 2009 we instituted an electronic NICU transfusion ordering and monitoring system as part of a new program to improve compliance with transfusion guidelines. In the four largest NICUs of Intermountain Healthcare, we performed a pre-post analysis of compliance with transfusion guidelines and transfusion usage. After beginning the new transfusion compliance program all four NICUs had an increase in compliance from 65% to 90%. Accompanying the improved compliance, all four NICUs had a reduction in transfusions administered. Specifically, compared with 2007 and 2008, there were 984 fewer NICU transfusions given in 2009. This included 554 fewer red blood cell (RBC) transfusions, 174 fewer platelet transfusions, and 256 fewer frozen plasma infusions. We calculate that in 2009, a total of 200 NICU patients who in previous years would have received one or more transfusions instead received none. Applying specific Intermountain Healthcare billing data to the observed transfusion reductions, this new program resulted in an annual decrease of $780,074 in blood bank charges (blood administration charges were not included). During the 3-year period, January 2007 through December 2009, we detected no change in NICU demographics, major morbidities, length of hospital stay, or mortality rate. Implementing a systemwide NICU program to improve compliance with already-established transfusion guidelines increased compliance from 65% to 90%. Improved compliance with transfusion guidelines was accompanied by a significant reduction in transfusions given, with no increase in NICU length of stay or mortality rate.
    Transfusion 02/2011; 51(2):264-9. DOI:10.1111/j.1537-2995.2010.02823.x · 3.57 Impact Factor
Show more